Last updated: Jun 27, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07262567 | 3 | Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer | KRAS G12D -- targeted inhibitor |
| NCT07605819 | — | Pancreatic Cancer Screening Using the Enzeavour Assay in Japan | Unknown mechanism |
| NCT07630961 | 1 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | Unknown mechanism |
| NCT07644559 | 2 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | KRAS G12D -- inhibitor (small molecule) |
| NCT07671339 | 1 | A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Tumor antigens -- peptide vaccine (ELI-002 7P) + PD-1 -- immune checkpoint inhibitor (Tislelizumab) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 21 |
| Zhejiang University | 13 |
| Tianjin Medical University Cancer Institute and Hospital | 12 |
| Ruijin Hospital | 12 |
| National Cancer Institute (NCI) | 8 |
Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 16, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | PSCA -- radiolabeled antibody fragment for imaging (radioconjugate) |
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Sep 30, 2026 | NCT07394205 | Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer | CLDN18.2 -- CAR-T cell therapy |
| Sep 8, 2026 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma | MEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC) |
| Aug 2026 | NCT07539155 | Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer | Measles, mumps, rubella virus antigens -- intratumoral vaccine |
| Jul 1, 2026 | NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | CDK7 -- kinase inhibitor (small molecule) |
| Jul 2026 | NCT07153289 | CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) | CD318 -- CAR-T cell therapy targeting CD318 |
| Jul 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
You've seen the pancreatic cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.